Adage Capital Partners
MRNA icon

Adage Capital Partners’s Moderna MRNA Stock Holding History

Adage Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Buy
+156,716
New +$8.11M 0.02% 702
2024
Q4 		– Sell
-102,898
Closed -$6.88M – 930
2024
Q3 		$6.88M Sell
102,898
-149,555
-59% -$13.7M 0.01% 678
2024
Q2 		$30M Buy
+252,453
New +$31.9M 0.06% 334
2024
Q1 		– Sell
-249,453
Closed -$24.8M – 928
2023
Q4 		$24.8M Sell
249,453
-63,763
-20% -$5.36M 0.05% 362
2023
Q3 		$32.4M Buy
313,216
+55,191
+21% +$6.16M 0.07% 275
2023
Q2 		$31.4M Sell
258,025
-33,973
-12% -$4.53M 0.07% 291
2023
Q1 		$44.8M Sell
291,998
-44,018
-13% -$7.26M 0.1% 236
2022
Q4 		$60.4M Buy
336,016
+3,300
+1% +$540K 0.14% 171
2022
Q3 		$39.3M Buy
332,716
+205,258
+161% +$31.1M 0.1% 223
2022
Q2 		$18.2M Sell
127,458
-230,858
-64% -$33M 0.04% 454
2022
Q1 		$61.7M Sell
358,316
-17,600
-5% -$2.96M 0.12% 180
2021
Q4 		$95.5M Buy
375,916
+48,788
+15% +$14.3M 0.17% 127
2021
Q3 		$126M Buy
+327,128
New +$121M 0.25% 87
2020
Q3 		– Sell
-325,000
Closed -$20.9M – 795
2020
Q2 		$20.9M Buy
+325,000
New +$17.8M 0.05% 376

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Adage Capital Partners's MRNA Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Moderna (MRNA) in Q2 2026: 156,716 shares worth $11M. The stake represents 0.02% of the portfolio and ranks #702 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in MRNA as recently as Q3 2024.

Adage Capital Partners first reported a position in MRNA in Q2 2020 and has held it in 14 quarters since. The position peaked at $126M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Adage Capital Partners held 156,716 shares of Moderna worth $11M as of Q2 2026.
  • Moderna was a new Adage Capital Partners position in Q2 2026.
  • Moderna made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #702 holding.
  • Adage Capital Partners first reported a position in Moderna in Q2 2020 and has held it in 14 quarters since.
  • Adage Capital Partners's Moderna position peaked at $126M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.